Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study.

Abstract

BACKGROUND:

Luteinizing hormone-releasing hormone (LHRH)-agonists in prostate cancer (PCa) patients induce sarcopenic obesity. The effect of LHRH-antagonist on body composition has never been explored. We evaluated changes in fat (FBM) and lean body mass (LBM) in PCa patients undergoing Degarelix.

METHODS:

This is a single-center prospective study, enrolling 29 non-metastatic PCa patients eligible to LHRH-antagonist from 2017 to 2019. All patients received monthly subcutaneous injection of Degarelix for 12 months. Changes in FBM and LBM between baseline and 12-month Degarelix, as measured by dual-energy x-ray absorptiometry, were the co-primary endpoints. Secondary endpoints were changes in serum lipids, glucose profile and follicle-stimulating hormone (FSH). Appendicular lean mass index (ALMI) and ALMI/FBM ratio were assessed as post-hoc analyses. Linear mixed models with random intercept tested for estimated least squared means differences (EMD).

RESULTS:

FBM significantly increased after 12 months (EMD +2920.7, +13.8%, p < 0.001), whereas LBM remained stable (EMD -187.1, -0.3%, p = 0.8). No differences occurred in lipid profile. Glycated hemoglobin significantly increased and serum FSH significantly decreased. A significant inverse relationship was found between serum FSH and ALMI/FBM ratio after 12 month (r = -0.44, p = 0.02).

CONCLUSIONS:

The BLADE study prospectively evaluated changes in body composition after LHRH-antagonist. LHRH-antagonist therapy is associated to an increased risk of obesity and diabetes, but lean body mass and serum lipids are not affected. This may represent an additional evidence supporting the reduced cardiovascular risk associated with LHRH-antagonist. The role of FSH in influencing sarcopenic obesity in PCa after androgen deprivation deserves to be further explored.

• Authors: Carlotta Palumbo, Alessandro Antonelli, Luca Triggiani, Alberto Dalla Volta, Filippo Maffezzoni, Stefania Zamboni, Paolo Borghetti, Luca Rinaudo, Francesca Valcamonico, Roberto Maroldi, Stefano Maria Magrini, Claudio Simeone, Alfredo Berruti, Collaborators
• Journal: Prostate cancer and prostatic diseases (Prostate Cancer Prostatic Dis) Vol. 24 Issue 3 Pg. 852-859 (09 2021) ISSN: 1476-5608 [Electronic] England
• PMID: 33723362 (Publication Type: Clinical Trial, Phase IV, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Chemical References

• Lipids
• Oligopeptides
• acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide

Topics

• Aged
• Body Composition
• Bone Neoplasms
• Follow-Up Studies
• Humans
• Lipids (blood)
• Male
• Middle Aged
• Oligopeptides (therapeutic use)
• Prognosis
• Prospective Studies
• Prostatic Neoplasms (blood, drug therapy, pathology)
• Survival Rate